REPH Stock: Recro Pharma Receives Daily Coverage Optimism Score of 0.16

0
129

Press coverage about Recro Pharma (NASDAQ:REPH) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Recro Pharma earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.2215621232642 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Recro Pharma (NASDAQ:REPH) traded up $0.05 during trading on Friday, hitting $9.38. 123,700 shares of the stock were exchanged, compared to its average volume of 118,569. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $10.17. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35.

A number of research firms have commented on REPH. Zacks Investment Research raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research report on Friday, October 27th. Finally, Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Monday, July 31st. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $12.88.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

LEAVE A REPLY

Please enter your comment!
Please enter your name here